Xiangrong Geng

Xiangrong Geng

Auto-generated profile, based on publicly available information

Xiangrong Geng

Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2022 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
XGXiangrong Geng
Xiangrong Geng
CWChenguang Wang
Chenguang Wang
XGXin Gao
Xin Gao
PCPinki Chowdhury
Pinki Chowdhury
JWJonathan Weiss
Jonathan Weiss
RWRyan Wilcox
Ryan Wilcox
Neoplasms originating from thymic T-cell progenitors and post-thymic mature T-cell subsets account for a minority of lymphoproliferative neoplasms. These T-cell derived neoplasms, while molecularly and genetically heterogeneous, exploit transcription factors and signaling pathways that are critically important in normal T-cell biology, including those implicated in antigen-, costimulatory-, and cytokine-receptor signaling. The transcription factor GATA-3 regulates the growth and proliferation of both immature and mature T cells and has recently been implicated in T-cell neoplasms, including the most common mature T-cell lymphoma observed in much of the Western world. Here we show that GATA-3 is a proto-oncogene across the spectrum of T-cell neoplasms, including those derived from T-cell progenitors and their mature progeny, and further define the transcriptional programs that are GATA-3 dependent, which include therapeutically targetable gene products. The discovery that p300-dependent acetylation regulates GATA-3 mediated transcription by attenuating DNA binding has novel therapeutic implications. As most patients afflicted with GATA-3 driven T-cell neoplasms will succumb to their disease within a few years of diagnosis, these findings suggest opportunities to improve outcomes for these patients.

2 January 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
XGXiangrong Geng
Xiangrong Geng
CWChenguang Wang
Chenguang Wang
SASuhaib Abdelrahman
Suhaib Abdelrahman
TPThilini Perera
Thilini Perera
BSBadeia Saed
Badeia Saed
RWRyan Wilcox
Ryan Wilcox
Purpose: Many peripheral and cutaneous T-cell lymphoma (CTCL) subtypes are poorly responsive to conventional chemotherapeutic agents and associated with dismal outcomes. The zinc finger transcription factor GATA-3 and the transcriptional program it instigates are oncogenic and highly expressed in various T-cell neoplasms. Posttranslational acetylation regulates GATA-3 DNA binding and target gene expression. Given the widespread use of histone deacetylase inhibitors (HDACi) in relapsed/refractory CTCL, we sought to examine the extent to which these agents attenuate the transcriptional landscape in these lymphomas. Experimental Design: Integrated GATA-3 chromatin immunoprecipitation sequencing and RNA sequencing analyses were performed in complementary cell line models and primary CTCL specimens treated with clinically available HDACi. Results: We observed that exposure to clinically available HDACi led to significant transcriptional reprogramming and increased GATA-3 acetylation. HDACi-dependent GATA-3 acetylation significantly impaired both its ability to bind DNA and transcriptionally regulate its target genes, thus leading to significant transcriptional reprogramming in HDACi-treated CTCL. Conclusions: Beyond shedding new light on the mechanism of action associated with HDACi in CTCL, these findings have significant implications for their use, both as single agents and in combination with other novel agents, in GATA-3–driven lymphoproliferative neoplasms.

27 November 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
CWChenguang Wang
Chenguang Wang
SASuhaib Abdelrahman
Suhaib Abdelrahman
XGXiangrong Geng
Xiangrong Geng
ABAlyssa Burgess
Alyssa Burgess
YHYing S. Hu
Ying S. Hu
RWRyan Wilcox
Ryan Wilcox
The transcription factor GATA-binding protein 3 (GATA-3) regulates oncogenic transcriptional programs across diverse T-cell lymphomas, including subsets of both peripheral and primary cutaneous T-cell lymphomas. These GATA-3 dependent transcriptional programs, in collaboration with the genetic landscape, promote cell growth and survival, and confer resistance to conventional chemotherapeutic agents. We observed that transcriptional cyclin dependent kinase 9 (CDK9) activation regulates diverse oncogenic transcriptional programs in these aggressive T-cell lymphomas and is thus a novel therapeutic vulnerability. Using complementary and orthogonal approaches, we identified multiple independent mechanisms by which CDK9 promotes T-cell lymphomagenesis, including a mechanism by which GATA-3 promotes CDK9 activation at GATA-3 dependent loci. We also identify novel mechanisms by which GATA-3 and CDK9 regulate rRNA transcription and processing, respectively, collaboratively promoting ribosome biogenesis. Therefore, CDK9 is a therapeutic vulnerability across genetically and transcriptionally diverse T-cell lymphomas, including those for which GATA-3 is oncogenic.

1 March 2024
Verified
Other
Open access
XGXiangrong Geng
Xiangrong Geng
CWChenguang Wang
Chenguang Wang
SASuhaib Abdelrahman
Suhaib Abdelrahman
TPThilini Perera
Thilini Perera
BSBadeia Saed
Badeia Saed
RWRyan Wilcox
Ryan Wilcox
List of HDACi altered GATA-3 target genes

1 March 2024
Verified
Other
Open access
PDF file
XGXiangrong Geng
Xiangrong Geng
CWChenguang Wang
Chenguang Wang
SASuhaib Abdelrahman
Suhaib Abdelrahman
TPThilini Perera
Thilini Perera
BSBadeia Saed
Badeia Saed
RWRyan Wilcox
Ryan Wilcox
BHLHE40 and KLF6 are transcriptionally activated by GATA-3, and their expression impaired upon HDAC inhibition

1 March 2024
Verified
Other
Open access
PDF file
XGXiangrong Geng
Xiangrong Geng
CWChenguang Wang
Chenguang Wang
SASuhaib Abdelrahman
Suhaib Abdelrahman
TPThilini Perera
Thilini Perera
BSBadeia Saed
Badeia Saed
RWRyan Wilcox
Ryan Wilcox
ChlP-seq occupancy binding peaks at GATA-3 target genes in vehicle/HDACi treated H9 cells